 |
Tan, Say Beng, PhD, CStat Other affiliations:
Associate Professor and Director, Duke-NUS Graduate Medical School, Singaproe, National University of Singapore Adjunct Associate Professor, Department of Epidemiology and Public Health, Yong Loo Lin School of Medicine, National University of Singapore
Principal Biostatistician, National Cancer Centre Singapore
E-Mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
|
Research Interests: Clinical trials and epidemiological studies in areas including
Applied biostatistics research, in particular Bayesian statistical approaches, clinical trial design methodology and statistical applications in cancer.
Selected Publications: Wong HB, Machin D, Tan SB, Wong TY, Saw SM (in press). Visual impairment and its impact on health-related quality of life in adolescents. American Journal of Opthalmology Tan SB, Wee J, Wong HB, Machin D (2008). Can external and subjective information ever be used to reduce the size of randomized controlled trials? Contemporary Clinical Trials 29: 211-219. Leong SS. Toh CK, Lim WT, Lin X, Tan SB, Poon D, Tay MH, Foo KF, Ho J, Tan EH (2007). A randomised phase II trial of single agent Gemcitabine, Vinorelbine or Docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. Journal of Thoracic Oncology 2: 230-236 Saw SM, Shankar A, Tan SB, Taylor H, Tan DTH, Stone RA, Wong TY (2006). A cohort study of incident myopia in Singaporean children. Investigative Opthalmology and Visual Science 47: 1839 – 1844 Ashby D, Tan SB (2005). Where’s the utility in Bayesian data-monitoring in clinical trials. Clinical Trials 2:197-208 Tan SB, Dear KBG, Bruzzi P, Machin D (2003). Strategy for randomised clinical trials in rare cancers. British Medical Journal 327: 47 – 49. Tan SB, Chung YFA, Tai BC, Cheung YB, Machin D (2003). Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. Controlled Clinical Trials 24: 110 – 121. Tan SB, Machin D (2002). Bayesian two-stage designs for Phase II clinical trials. Statistics in Medicine 21: 1991 – 2012. Tan SB, Machin D, Cheung YB, Chung YFA, Tai BC (2002). Following a trial that stopped early: What next for adjuvant hepatic intra-arterial iodine-131-lipiodol in resectable hepatocellular carcinoma? Journal of Clinical Oncology 20: 1709. Tan SB, Machin D, Tai BC, Foo KF, Tan EH (2002). A Bayesian re-assessment of two phase II trials of Gemcitabine in metastatic nasopharyngeal cancer. British Journal of Cancer 86: 843-850. |
||
